Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17965894 | 0.90 | CKS1B (0.49) | CKS1BSKP1SKP2OPRK1SUV39H2 | |
| SCHEMBL17007074 | 0.83 | CKS1B (0.56) | CKS1BSKP1SKP2OPRK1PARP1 | |
| SCHEMBL16694507 | 0.82 | SSTR2 (0.52) | CKS1BSKP1SKP2OPRK1SUV39H2 | |
| SCHEMBL16608976 | 0.81 | CKS1B (0.45) | CKS1BSKP1SKP2OPRK1SUV39H2 | |
| SCHEMBL21248739 | 0.79 | JAK3 (0.47) | CKS1BSKP1SKP2SUV39H2CTSK | |
| SCHEMBL21248737 | 0.79 | JAK3 (0.47) | CKS1BSKP1SKP2SUV39H2CTSK | |
| Phosphoric Acid SCHEMBL16694996 | 0.79 | CKS1B (0.51) | CKS1BSKP1SKP2OPRK1PARP1 | |
| SCHEMBL21056645 | 0.78 | CKS1B (0.50) | CKS1BSKP1SKP2OPRK1SUV39H2 | |
| SCHEMBL16944494 | 0.78 | OPRK1 (0.71) | OPRK1 | |
| SCHEMBL24456772 | 0.78 | CKS1B (0.52) | CKS1BSKP1SKP2OPRK1SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3053916-B1 | COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-20180194775-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-9975904-B2 | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170183359-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-29 | — | — | US | disclosed |
| US-9643951-B2 | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9630976-B2 | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20160311794-A1 | COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20150232478-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-20 | — | — | US | disclosed |
| EP-2871179-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | ONO Pharmaceutical Co., Ltd. (JP) | 2015-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183359-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | SSTR2, SSTR1, SSTR3 | CKS1B 4744/4885SKP1 961/4885SKP2 2652/4885 |
| US-20150232478-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | SSTR2, SSTR1, SSTR3 | CKS1B 4734/4885SKP1 1112/4885SKP2 2836/4885 |
| US-20160311794-A1 | COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF | SSTR1, SSTR2, SSTR3 | CKS1B 4574/4885SKP1 1214/4885SKP2 2862/4885 |
| US-20180194775-A1 | COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES | SSTR2, SSTR1, SSTR3 | CKS1B 4744/4885SKP1 961/4885SKP2 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.